This bill, known as the Cure Hepatitis C Act of 2026, directs the Secretary of Health and Human Services to establish a comprehensive program aimed at eliminating hepatitis C virus in the United States. Within 90 days of enactment, the Secretary must create the Hepatitis C Elimination Program , followed by a national strategy and implementation plan within 180 days. This plan will outline specific goals, objectives, and strategies for prevention, detection, and treatment, including identifying priority populations and assessing existing federal efforts. To support the program, the bill mandates the establishment of an advisory committee, comprising individuals with lived experience, clinicians, public health officials, and industry representatives, to provide guidance to the Secretary. An interagency working group, including leaders from various federal agencies like the CDC, HRSA, and CMS, will also be formed to aid in the program's development and evaluation. A publicly available dashboard will be maintained to monitor progress, and the Secretary is required to engage with stakeholders and submit annual reports to Congress. A core component of the bill is the establishment of a subscription program for hepatitis C treatments . Under this model, the Secretary will enter into 5-year agreements with drug manufacturers to purchase an unlimited supply of direct-acting antiviral drugs for a fixed annual fee. These treatments will be distributed to registered pharmacies, participating state and local correctional systems, the Bureau of Prisons, and Indian Health Service facilities, with no cost-sharing for eligible individuals. The covered populations for this subscription program include individuals enrolled in participating State Medicaid or CHIP programs, those confined in federal or participating state/local correctional facilities (including continued treatment post-release), individuals without minimum essential health coverage, and those receiving care through Indian health programs. State and local correctional systems must opt into the program and agree to conditions such as not imposing prior authorization requirements for hepatitis C treatment and ensuring continued care for released individuals. The bill also authorizes substantial funding for public health activities to support hepatitis C elimination. The Secretary will award grants to states and political subdivisions to improve outreach, increase screening and treatment rates, and coordinate health and social services for high-risk individuals. These funds can also be used to enhance public health capacities related to prevention, detection, diagnosis, and outbreak response, with specific awards targeting opioid treatment programs, tribal areas, community health centers, correctional facilities, and Ryan White clinics. Further provisions include technical assistance for states, coordination with existing hepatitis B and opioid use disorder efforts, and the potential for purchasing and distributing point-of-care diagnostic tests. A national provider training network will be established to offer technical assistance on hepatitis C care, and a public awareness and education campaign will be launched. The bill appropriates $5.5 billion for the subscription program and an additional $4.283 billion for public health activities and program administration for fiscal year 2027 through 2033. Additionally, it amends the Social Security Act to eliminate cost-sharing and deductibles for direct-acting antiviral hepatitis C treatments under Medicare Part D for plan years 2028 through 2032.